Aldosterone synthase inhibitor “Baxdrostat” for resistant hypertension: A clinical approach or futuristic idea?

Hypertension and human health: Evidence and prospects

“…Although many guidelines have reached consensus on first‐line antihypertensive drugs, including angiotensin‐converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, β‐blockers, and thiazide diuretics, 14 the development of new antihypertensive agents is yet to be promising 15 . Baxdrostat, an aldosterone synthesis inhibitor, was tested in a phase II trial involving 274 patients with resistant hypertension who were randomized postscreening 16 . It demonstrated high potency without influencing cortisol levels and had a favorable safety performance.…”

“… 15 Baxdrostat, an aldosterone synthesis inhibitor, was tested in a phase II trial involving 274 patients with resistant hypertension who were randomized postscreening. 16 It demonstrated high potency without influencing cortisol levels and had a favorable safety performance. However, further studies are required to validate these findings.…”